June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Rami Manochakian: Tarlatamab vs Chemotherapy in second treatment for advanced SCLC
Jun 3, 2025, 09:56

Rami Manochakian: Tarlatamab vs Chemotherapy in second treatment for advanced SCLC

Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared on X:

“Hot Off The Press!
Just published in NEJM in conjunction with presentation at ASCO 2025.
Results of DeLLphi304 phase trial of Tarlatamab vs Chemotherapy in 2nd treatment for advanced Small Cell Lung Cancer.
  • mOS: 13.6 vs 8.3 months (HR: 0.6)
  • More Improvement in symptoms with Tarlatamab
  • ≥ Grade 3 AEs: 54% vs 80%
  • CRS and ICANS mostly grade 1/2.”

Rami Manochakian: Tarlatamab vs Chemotherapy in second treatment for advanced SCLC

Read OncoDaily’s special articles:

Tarlatamab (Imdelltra): Uses in Cancer, Side Effects, Dosages, Expectations, and More

Tarlatamab (Imdelltra): What Patients Need to Know About